P/E at 29.8 vs Industry's 36.8: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 29.81, which is approximately 19% lower than the Pharmaceuticals & Biotechnology industry average of 36.83. This discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Given the sector’s generally robust earnings growth, the valuation gap invites scrutiny — Dr Reddys Laboratories Ltd’s lower multiple could reflect concerns about recent operational performance or competitive pressures. What does this valuation discount imply for investors assessing the stock’s prospects?

Performance Across Timeframes: A Consistent Underperformer

Examining returns over multiple periods reveals persistent underperformance relative to the Sensex. Over the past year, Dr Reddys Laboratories Ltd has declined by 11.15%, compared to the Sensex’s 4.89% fall. The divergence widens over shorter horizons: the stock has lost 15.56% in the last three months while the Sensex edged up 0.06%. This sharp recent weakness is compounded by a 15.26% drop over the past month, contrasting with a marginal 0.21% decline in the benchmark. The one-week and one-day performances also show the stock lagging, with losses of 5.18% and 0.60% respectively, against the Sensex’s more modest declines or gains. Is this sustained underperformance signalling structural challenges or a cyclical trough?

Moving Average Configuration: Bearish Technical Setup

The technical picture for Dr Reddys Laboratories Ltd is decidedly negative. The stock is trading below all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day — indicating a broad downtrend across short, medium, and long-term horizons. This configuration suggests that recent rallies, if any, have failed to gain traction and the stock remains under selling pressure. The six-day consecutive losing streak, with a cumulative decline of 6.23%, reinforces the bearish momentum. Could this be a recovery in waiting or a continuation of the downtrend?

Sector Context: Mixed Results Amidst Stability

The Pharmaceuticals & Biotechnology sector has seen a balanced set of results recently, with four stocks reporting earnings: two positive and two flat, and none negative. This suggests a broadly stable sector environment, though not without challenges. Against this backdrop, Dr Reddys Laboratories Ltd’s underperformance stands out. The stock’s market capitalisation of ₹95,486.91 crores places it in the mid-cap category, where volatility can be more pronounced than in larger peers. How does the stock’s performance compare with other mid-cap pharmaceuticals players?

Rating Reassessment: Previously Hold, Now Updated

On 13 Jul 2026, the rating for Dr Reddys Laboratories Ltd was updated from Hold to a new assessment. The previous Mojo Score was 36.0, with a Hold grade assigned by MarketsMOJO. This change reflects the evolving data landscape, including valuation, performance, and technical indicators. The rating update invites investors to reconsider the stock’s positioning within their portfolios — should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider?

Long-Term Performance: Lagging Behind the Benchmark

Looking beyond the recent periods, the stock’s long-term returns also trail the Sensex. Over three years, Dr Reddys Laboratories Ltd has delivered a modest 2.37% gain, compared to the Sensex’s 16.29%. The five-year return of 20.93% similarly lags the benchmark’s 46.70%, and over ten years, the stock’s 93.20% gain is well below the Sensex’s 172.74%. This persistent underperformance over extended periods highlights challenges in sustaining growth and market leadership. Is this a reflection of sector dynamics or company-specific factors?

Summary: A Complex Data Story

The data for Dr Reddys Laboratories Ltd reveals a stock trading at a valuation discount to its sector, yet suffering from consistent underperformance across short, medium, and long-term horizons. The technical indicators confirm a bearish trend, with the stock below all major moving averages and enduring a multi-day losing streak. Sector results remain mixed but stable, offering no clear tailwind. The recent rating reassessment from Hold signals a shift in the stock’s outlook, though the direction is not disclosed. Collectively, these factors present a nuanced picture — what is the current rating for Dr Reddys Laboratories Ltd, and how should investors interpret this data?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today